

Docket No. 244288US0DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hiroyuki ISHIWATA, et al.

SERIAL NO: New Application

GAU:

FILED: Herewith

EXAMINER:

FOR: BIS (5-ARYL-2-PYRIDYL) DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. All of the listed references are of record in prior application Serial No. 09/893,698, filed June 29, 2001.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Frederick D. Vastine, Ph.D.

Registration No. 27,013

Docket No. 244288US0DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hiroyuki ISHIWATA, et al.

SERIAL NO: New Application

GAU:

FILED: Herewith

EXAMINER:

FOR: BIS (5-ARYL-2-PYRIDYL) DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. All of the listed references are of record in prior application Serial No. 09/893,698, filed June 29, 2001.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Frederick D. Vastine, Ph.D.

Registration No. 27,013

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 244288US0DIV		SERIAL NO. New Application	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroyuki ISHIWATA, et al.			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	1-106818	04/24/89	JAPAN (w/English abstract)		xx	
	AP	7-017506	03/01/95	JAPAN (w/English abstract)		xx	
	AQ	8-092216	04/09/96	JAPAN (w/English abstract)		xx	
	AR	8-109177	04/30/96	JAPAN (w/English abstract)		xx	
	AS	10-324631	12/08/98	JAPAN (w/English abstract)		xx	
	AT	11-269192	10/05/99	JAPAN (w/English abstract)		xx	
	AU	59-167564	09/21/84	JAPAN (w/English abstract)		xx	
	AV	WO 96/11682	1996	WIPO (corr. EP 0 787 491)			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	Cas printout for Hagen et al., Synthesis and cardiovascular properties of 5-(4-pyridinyl)-, 6-methyl-5-(4-pyridinyl)- and 6-methyl 5-phenyl -substituted 3-cyano-2-aminoalkylaminopyridines, Pharmazie 45: 240-241, 1990.					
	AX	Robert B. Fick, Jr., Current Opinion in Pulmonary Medicine, vol. 5, pages 76-80, "ANTI-IgE AS NOVEL THERAPY FOR THE TREATMENT OF ASTHMA", 1999.					
	AY	Farhad Imani, Emerging Therapeutic Targets, vol. 3, no. 2, pages 229-240, "EMERGING THERAPEUTIC TARGETS IN ASTHMA AND ALLERGY: MODULATION OF IgE", 1999.					
	AZ	Henry Milgrom, et al., The New England Journal of Medicine, vol. 341, no. 26, pages 1966-1973, "TREATMENT OF ALLERGIC ASTHMA WITH MONOCLONAL ANTI-IgE ANTIBODY", December 23, 1999.				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 244288US0DIV		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroyuki ISHIWATA, et al.			
				FILING DATE HEREWITH		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AAA						
	AAB						
	AAC						
	AAD						
	AAE						
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AAQ	0 787 491	08/06/97	EUROPE			
	AAP	WO 98/04508	02/05/98	WIPO (w/English abstract)		xx	
	AAQ	WO 98/07702	02/26/98	WIPO (w/English abstract)		xx	
	AAR	WO 98/16497	04/23/98	WIPO (w/English abstract)		xx	
	AAS	WO 99/19291	04/22/99	WIPO (w/English abstract)		xx	
	AAT	WO 99/35140	07/15/99	WIPO			
	AAU	WO 99/38829	08/05/99	WIPO (w/English abstract)		xx	
	AAV	WO 99/42446	08/26/99	WIPO (w/English abstract)		xx	
	AAW	WO 00/05198	02/03/00	WIPO (w/English abstract)		xx	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AAX	Naosuke Matsuura, et al., Jpn. Pharmacol. Ther., vol. 22, no. 3, pages 1369-1383, "AN IMMUNOPHARMACOLOGICAL STUDY OF (±) - [2- [4-(3-ETHOXY-2-HYDROXYPROPOXY) PHENYL CARBAMOYL] ETHYL] DIMETHYLSULFONIUM P-TOLUENESULFONATE (SUPLATAST TOSILATE, IPD-1151T)", 1994.					
	AAZ						
Examiner					<input type="checkbox"/> Additional References sheet(s) attached		
Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							